CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

Author's Avatar
Apr 13, 2020
Article's Main Image

CNS Pharmaceuticals to receive 50% of net sales on resulting anti-viral commercial products, including WP1122, in certain international markets

PR Newswire